The FDA has approved GlaxoSmithKline (GSK)’s belantamab mafodotin for relapsed or refractory multiple myeloma. The antibody–drug conjugate (ADC) is the first therapeutic from the crowded BCMA-targeted pipeline to secure approval. Para acessar a publicação na íntegra clique aqui Fonte: Nature Reviews | Drug Discovery volume 19 | OCTOBER 2020 | 659…